ID3

inhibitor of DNA binding 3

Explore in graph →CI-GENE-00005335HGNC:5362 ENSG00000117318 NCBI 3399 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ID3 mutation1
(oncogenic)	Burkitt Lymphoma	Oncogenic	E	Supports Oncogenicity	4	submitted	EID11841 ID3 mutations have been firmly established as a distinguishing genetic feature of BL and are one of the defining mutations in the new BL genetic subgrouping system proposed by Thomas et al PMID 23143595 · Richter et al., 2012 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (12)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved12 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Mature B-Cell Neoplasms (Simon Fraser University, Blood 2023) mbn_sfu_2023	B-Cell Non-Hodgkin Lymphoma	Ssm	115

Literature

Linked publications (0)

Data not yet available

No publication linked to this gene yet.